Heart failure (HF) is a rapidly growing public health issue with an estimated prevalence of >37.7 million individuals globally. HF is a shared chronic phase of cardiac functional impairment secondary to many aetiologies, and patients with HF experience a range of symptoms that affect their quality of life, including dyspnoea, fatigue, poor exercise tolerance and fluid retention.

The burden of HF will continue to rise, due to population aging, population growth and improved treatment of HF and other cardiovascular disorders. As a result, clinicians will be increasingly challenged to develop treatment plans and care systems that reduce the high levels of morbidity and mortality experienced by these patients, both from their HF and other comorbidities.

Related Articles


Corrigendum to: Sodium–glucose Cotransporter 2 Inhibitors in Heart Failure…

Juan Tamargo,


Citation: European Cardiology Review 2019;14(3):201

Asymptomatic Left Ventricle Systolic Dysfunction

Jaskanwal D Sara, Takumi Toya, Riad Taher,


Citation: European Cardiology Review 2020;15:e13.

Heart Failure Treatment by Device

Antoni Bayés-Genís,


Citation: European Cardiology Review 2020;15:e17.

Interatrial Shunting for Left Heart Failure

Leonardo Guimaraes, David del Val, Sebastien Bergeron,


Citation: European Cardiology Review 2020;15:e18.